Abstract
Sublingual dexmedetomidine under the tradename of IgalmiTM is the first and only FDA-approved sedative agent for treating agitation in schizophrenia and bipolar I or II patients. This article highlights the benefits and adverse effects associated with this novel route of administration of dexmedetomidine and its potential to emerge as a promising sedative agent.